Vertex Pharmaceuticals (NasdaqGS:VRTX) is reassessing its pain management program after disappointing FDA label discussions for Journavx. Phase II data for pain candidate VX-993 did not meet ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is among the most profitable healthcare stocks to buy. On January 26, UBS ...

Description: Honey finds coupons with one click. Thanks to Honey for sponsoring! Keyboard build (affiliate links below) ...

Under the agreement, participating states will receive “discounts and rebates” from the drugmakers if the treatments don’t ...

Pro and Ultra subscribers now get monthly Google Cloud credits, part of an end to end build to deploy workflow.

As Gianakakos, Chief Medical Officer Edelberg and the rest of the Kardigan team continue developing their pipeline through ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...

Google has recently announced a significant update to its premium AI subscriptions, introducing built-in developer tools and cloud credits for Google AI Pro and Google AI Ultra subscribers. This ...

Satellos Bioscience Inc., a clinical-stage biotechnology company, has appointed Antoinette Paone as Chief Development Officer ...

Google has introduced new developer tools and cloud credits to its premium AI subscriptions, aiming to streamline the development process from prototype to production.

Both platforms are backed by over 50 peer-reviewed publications representing decades of development. The addressable markets span multiple areas: Alzheimer's disease ($32.8 billion by 2033), ...